2024The Frost & Sullivan New Investment Summit in Life Sciences has successfully concluded!
Global growth consulting leader Frost & Sullivan(Frost & SullivanAbbreviation: Frost & Sullivan)The 18th Frost & Sullivan China Growth, Innovation & Leadership Summit and the 3rd New Investment Conference (hereinafter referred to as:2024The New Investment Conference of Frost & Sullivan) in2024year8month28 - 30The event is held in Shanghai every day.
2024During the Frost & Sullivan New Investment Conference, a comprehensive report titled1.5The New Investment Summit Forum on Life Sciences of Tianjin. The forum brought together40Several industry leaders, biopharmaceutical companies, medical device enterprises, investment institutions, and professional service providers, with the theme of 'Adapting to Changes and Opening New Horizons', gathered to discuss new models of investment cooperation. The aim is to build a closer, more efficient, and mutually beneficial cooperation network, jointly promoting the vigorous development of the domestic and international life science industry.
The New Investment Summit Forum on Life Sciences has been held8month29The afternoon session concluded successfully.
NIE 2024
Highlights ·8month28day Plenary Session
Guest Speech
President of the China Hepatitis Prevention and Control Foundation, former Director of the Chinese Center for Disease Control and Prevention Professor Wang Yu
Professor Wang Yu pointed out that the global pharmaceutical market is on a track of rapid expansion, having achieved a significant growth of $800 billion in the past four years, and predicts that it will increase further within the next decade.1.3Trillions of dollars demonstrate strong growth potential and market prospects. Although North America and Europe, as traditional major markets, still hold a leading position, these markets have matured and are mainly dominated by large pharmaceutical companies. At the same time, emerging developing countries have made remarkable progress in the pharmaceutical market, with significant increases in health expenditures, indicating an urgent need for high-quality medical resources.
Opening Remarks by the Organizer
Global Partner and Chairman of Frost & Sullivan Greater China Region Dr. Wang Xin
Dr. Wang Xin emphasized that given China's status as the most populous country in the world, its per capita GDP has crossed the ten-thousand-yuan mark and maintained a high-quality economic growth trend. This backdrop has directly spurred a huge growth in healthcare demand. In the face of inherent uncertainties and challenges in the market environment, relevant enterprises need to have a long-term vision and make adequate long-term strategic plans. By deepening close cooperation among industry-university-research (i.e., industry, academia, and research institutions), the investment community, and the media, a collaborative and symbiotic ecosystem with complementary advantages can be jointly constructed. Such an ecosystem can not only promote technological innovation and achievement transformation but also effectively respond to market changes, ensuring that enterprises maintain competitiveness in the complex and ever-changing healthcare market and continuously drive the prosperous development of the healthcare industry.
Keynote Speech
Executive President and Secretary-General of Shanghai Biomedical Industry Association Chen Shaoxiong
Chen Shaoxiong pointed out that the future of biomedicine will be an industry with strong demand and rapid development and iteration. In the face of current development status and opportunities, Shanghai's biomedicine industry is accelerating its industrial upgrading through policy support and strategic planning. In the wave of technological and industrial transformation, how to maintain a leading position and gain advantages in global competition has become the focus of current attention. The scale of Shanghai's pharmaceutical and medical device market has exceeded 230 billion yuan. The government has introduced a series of policy measures, including accelerating the application and promotion of innovative products, strengthening investment and financing support, unlocking the value of data elements, and promoting international industrial development. These measures will help Shanghai build a global innovation highland for the biomedicine industry and promote its international development.
Vice President of Business Development and Strategic Innovation, Greater China at BD Medical Golden Carriage
Jin Jia pointed out that BDI Medical has been deeply involved in the Chinese market for over a decade. The key to its success lies in the implementation of a localization strategy, with talent localization being at its core. Through localized integration of the supply chain, localized innovation in R&D, and efforts in localizing the entire chain of production, sales, and services, BDI Medical is committed to creating a high-quality model of a localized multinational enterprise, thereby contributing to the sustainable development of China's medical industry. Localization practices cover all aspects from talent, supply chain, R&D to production, sales, and after-sales service. Therefore, despite numerous challenges, promoting the comprehensive localization of China's pharmaceutical industry remains an important direction for achieving long-term healthy industry development.
Chairman of Farimetrics Medical Professor Yin Qingfeng
Professor Yin Qingfeng pointed out that traditional Chinese medicine (TCM), as an important part of Chinese traditional culture, is facing significant opportunities. New productive forces, through means such as technological innovation, industrial upgrading, and talent cultivation, are driving the TCM industry towards high-quality development and transformation. Practice has shown that new productive forces have achieved remarkable results in promoting the modernization of the TCM industry, providing strong support for enhancing the status of TCM in the global healthcare system. In the future, TCM will continue to expand its influence globally by further integrating with modern medicine, and contribute to the internationalization process of TCM.
"The2024Release Ceremony of the Blue Book on the Current Situation and Trends of Chinese Biopharmaceuticals Going Global
Partner and Managing Director of Frost & Sullivan Greater China Region fattening
Mao Hua introduced, stepping in2024In [year], China's pharmaceutical product exports gradually returned to a stable track. It is worth noting that the export share of formulation products still has significant growth potential waiting to be tapped. Mao Hua pointed out that in the field of innovative drugs, since2019Since the beginning of this year, Chinese enterprises have significantly accelerated their pace of independent overseas expansion. This trend is evident in2023Achieving a new milestone in the yearlicense-out operationTrading volume exceeds for the first timelicense-in grant, especiallyADCThe drug sector has become a hot topic in transactions, highlighting China's rise in the field of innovative drug research and development. In addition, since2023Since the end of the year, several local biotechnology companies have been acquired by multinational pharmaceutical giants. This series of mergers and acquisitions is not only an international recognition of the R&D strength and technological innovation of Chinese pharmaceutical companies but also indicates that China's biopharmaceutical industry is accelerating its integration into the global pharmaceutical innovation ecosystem.
"The2024Hong Kong stocks for the year18ARelease Ceremony of the "Biotech Startup Investment Activity Report"
Chairman and Chief Executive Officer of SULLIVAN TELE-TREND CLOUD TECHNOLOGY, TradeGo Wan Yong
Wan Yong pointed out that as of2024year3month31Hong Kong stocks18ABiotechnology companies in total64The company has completed its listing, covering small molecule drugs, nucleic acid drugs, antibody drugs,AIInnovation pharmaceutical tracks such as medical imaging.64The company is listed18AThe total fundraising amount of the company reached1,111.18HK$10 billion,2022 - 2024year3Average monthly fundraising per company4.62HK$10 billion. As of2024year3month31days, a total of12The company completed “acquisitionB"Overall average", "excluding-B"Duration required684day,18home18AThe total amount of refinancing obtained through placement by the Company is approximately582.90HK$10 billion.
NIE 2024
Highlights ·8month29day
New Investment Summit Forum in Life Sciences (Parallel Session)
Medicine Session
Opening Remarks
New Investment Summit in Life Sciences (Parallel Session) - Pharmaceutical Special Session, hosted by Mr. Mao Hua, Partner and Managing Director of Frost & Sullivan Greater China, commenced with a welcome speech.
Guest Speech
Founder and Executive Chairman of Shanghai Chuangqi Health Development Research Institute Professor Cai Jiangnan
Professor Cai Jiangnan introduced that the Chinese innovative drug market is in a stage of rapid development, but it still faces many challenges in terms of market access. Market access has become a core content that needs to be considered and implemented throughout the entire lifecycle of innovative drugs, and how to define value has become the core of market access. Innovative drugs not only need to possess clinical value but also demonstrate their unique advantages in terms of commercial, economic, and social value. To achieve this goal, stakeholders such as medical insurance, hospitals, enterprises, and patients need to jointly establish a consensus on value, find the greatest common divisor of values, and promote the success of innovative drugs in the market.
Keynote Speech
VivoTech's Deputy General Manager and Chief Scientific Officer Dr. Pande
Dr. Pande emphasized that thanks to the active support of national policies and strong guarantees for the entire R&D chain of domestic innovative drugs, the industry has significantly enhanced its status at home and abroad. Especially in the field of artificial intelligence (AIThe integration of technology has greatly accelerated the early stages of drug research and development, effectively improving R&D efficiency. However, in the face of rapid industry changes, while actively adopting new tools and technologies, enterprises must unswervingly maintain their pursuit and commitment to the essence of innovative drugs. Only in this way can enterprises consolidate their foundation in a highly competitive market and achieve sustainable growth and development.
Global Head of Science and Technology at Thermo Fisher Scientific's Pharmaceutical Services DivisionDr. Anil Kane
Dr. Anil KaneIt is emphasized that China's pharmaceutical R&D market is in a period of rapid growth, with its global influence significantly enhanced. It has become one of the core forces in the field of new drug R&D. In the past three years, the prosperity of global outsourcing business has drivenCDMO companyEnterprises have become a key driving force in drug research and development, not only helping pharmaceutical companies cross borders but also facilitating efficient transactions of clinical pipelines. Looking ahead to the next five years, China's pharmaceutical industry is expected to further deepen its collaboration with the global community, leveraging its solid R&D foundation and massive market demand.CDMO companyEnterprise cooperation.CDMO companyAs a bridge, the enterprise is working together to draw a grand blueprint for diversified and efficient drug development.
BFC Groupdirector Lu Qiwen
Lu Qiwen pointed out that over the past thirteen years, in the field of healthcare in ChinaBDAverage annual trading volume3.63%The compound growth rate continues to increase, indicating a strong development momentum of the industry.2016Since the beginning of this year, in the field of healthcare in ChinaBDThe number of transactions in the trading year has remained stable at over 100, and in2020Record high in the new year. Entered2024In the first half of the year, cross-border outsourcing licensing transactions accounted for a significant proportion, reaching as high as53%The oncology field continues to lead and has become the most active therapeutic area. At the same time, small molecule drugs and monoclonal antibodies dominate in licensing transactions, while antibody conjugates (ADCThe transaction volume of ( ) has also increased significantly, indicating a continuous enhancement of the industry's innovative vitality.
Chief Scientific Officer, Corning Botai Dr. Tan Xiangyang
Dr. Tan Xiangyang pointed out,2024First half of the yearADCThe project has experienced explosive growth, compared to2023Bottom addition21%The target trend shows a situation where homogenized competition and innovation coexist, while in terms of toxins, there is a gradual trend towards seeking balance between toxicity and efficacy. There are a wide variety of new conjugated drugs, with continuous technological innovation, and the global trend of 'everything can be linked' is becoming increasingly evident. In ChinaADCThe company leads the world in R&D volume, and its target layout is gradually transforming from following to innovation. HoweverADCThe clinical success rate of the drug is only10%Its design complexity is much higher than that of traditional antibody drugs and chemical drugs, and ideal targets are difficult to achieve. Next-generationADCTechnology is exploring more precise target design, innovative toxins, and combination drug strategies.
Founder and CEO of Sanyidian Medicine Dr. Seiichiro Asahara
Dr. Seiichi Saito emphasized,3DThe application of printing technology in the field of pharmaceutical manufacturing is revolutionizing the pharmaceutical industry in a transformative way. This innovative technology not only transforms the methods of drug research and development, delivery, and production but alsoMEDAdvanced means have ensured a significant improvement in the precision of drug release, production efficiency, and success rate. In addition,3DPrinting pharmaceuticals also demonstrates multiple advantages such as quality stability, cost-effectiveness, and environmental friendliness. As per the US Food and Drug Administration (FDA) Clearly approved technologies,3DThe printing of the drug has also been approved by the National Medical Products Administration of China (NMPAIts promotion is regarded as a benchmark for continuous production technology.
Chairman of FuKang Pharmaceutical Dr. Shen Xiaokun
Dr. Shen Xiaokun pointed out that global new drug development is showing a continuous growth trend, and investment hotspots in biomedicine are focused on oncology andAIdomain although2022The global expansion rate of new drug approvals slowed down to8.2%, but there are still1,183A new drug has entered the development phase, wherein40.7%Anticancer drug.AITechnology has played a key role in new drug research and development, significantly improving R&D efficiency by accelerating target discovery, optimizing clinical trial designs, and exploring new indications for existing drugs.
General Manager Lan Na Cheng Wu Xiaoming
Wu Xiaoming pointed out that although China's nuclear pharmaceutical industry faces challenges such as insufficient radionuclide supply and restricted imports, the localization and industrial chain of nuclear drugs are undergoing changes against the backdrop of the country's strong promotion of nuclear medicine development. Currently, there are few products on the market for nuclear drugs, especially in the field of therapeutic nuclear drugs, which still mainly consist of traditional products, and the industrial ecosystem has not fully matured. However, with policy guidance and innovation-driven efforts, more capital and enterprises are actively participating in the nuclear medicine field, promoting the research, development, and marketing of integrated diagnostic and therapeutic nuclear drug products. The expansion of the Chinese nuclear pharmaceutical market will promote the gradual internationalization of products and lead to the sustained development of the global nuclear pharmaceutical industry.
Roundtable discussion
Roundtable Discussion: How to Seize Opportunities from Breaking the Mold from 'Involution' to 'Going Global'
The first roundtable discussion was themed 'Breaking the Mold from 'involution' to 'going global': How to Seize Opportunities'. The roundtable was moderated by Liu Da, Managing Director of China Resources Vanguard Life Sciences Fund, and co-founder of Qide Medicine.CEOQin Gang, Chairman and President of Nuoyuan Medical, Cai Huiming, Vice President and Investor Relations & Corporate Development Director of Hebo Medicine, Chen Youchen, Vice President of Ireland's Investment Development Board for Life Sciences, and Xiao Jia, Director of the Life Sciences Industry at the Irish Investment Development Board, participated in the discussion as guests. During the discussion, they jointly explored how biopharmaceutical companies can find new growth opportunities in the current highly competitive market environment, transition from domestic 'involution' to international 'going global', and seize opportunities for long-term development.
Roundtable Discussion: Act in accordance with the times and follow the trend: Commercialization Strategies of Chinese Innovative Pharmaceutical Companies
The second roundtable focused on the theme 'Acting in Times and Trends: Commercialization Strategies of Chinese Innovative Pharmaceutical Companies'. The discussion was chaired by Gong Li, Managing Director and Head of the Healthcare Investment Banking Group at CICC. The panelists included Zhang Jinhua, Founder, Chairman and CEO of Xunluo Biotech; Dr. Wang Haibin, CEO of Borui Biotech; Lu Huiping, Executive Deputy General Manager of Zhejiang Genomics & Therapeutics Co., Ltd.; and Zhang Jing, Chief Financial Officer of SinoCure Biologics.
During this roundtable discussion, the panelists engaged in an in-depth exploration of how Chinese innovative pharmaceutical companies can formulate and execute effective commercial strategies in a rapidly changing market environment. They shared their respective insights, discussed how to accurately grasp opportunities, actively adapt to and lead the mainstream trends of industry development, and ensure competitiveness in a rapidly changing market environment.
NIE 2024
Highlights ·8month29day
New Investment Summit Forum in Life Sciences (Parallel Session)
Instrument Session
Opening Remarks
New Investment Summit in Life Sciences (Parallel Session) - The Medical Devices Session was hosted by Mr. Wang Chenhui, Managing Partner and President of Frost & Sullivan Greater China.
Guest Speech
Executive Vice President of China Medical Device Industry Association and Chairman of the National Medical Device Industry Technology Innovation Alliance of the Ministry of Science and Technology Dr. Jiang Feng
Dr. Jiang Feng pointed out that despite the challenges of a slowdown in growth rate faced by the medical device industry in the first half of the year, its overall development prospects are still widely optimistic, demonstrating strong resilience. In China, the medical device industry is thriving at an unprecedented pace, relying on its solid industrial foundation and the massive market volume accumulated over the past. Coupled with continuous support from national policy levels, the industry is highly anticipated and is expected to surpass Japan in the future, becoming a leader in the global medical device field. It is worth noting that although the current share of the Chinese medical device market only accounts for one-third of the total medical market size, referring to the mature paths of developed countries, the medical device and pharmaceutical markets often develop side by side, indicating tremendous growth potential.
Keynote Speech
General Manager of Kunmai Medical Dr. Sheng Jingwei
Dr. Sheng Jingwei pointed out that functional imaging technology is gradually becoming an important tool for the diagnosis and treatment of brain diseases and brain research in the future. The new generation of functional imaging technology is trending towards higher resolution, more portable forms, and more personalized applications, providing strong support for the progress of brain science. Multimodal fusion imaging is an inevitable path in the development of current brain imaging technology and will further promote leapfrog development in brain science, clinical brain research, and brain intelligence. These innovative technologies not only improve the accuracy of diagnosis but also provide new possibilities for formulating more effective treatment plans.
Brain auroraCEODr. Wang Xiaoyi
Dr. Wang Xiaoyi pointed out that digital therapies are gradually demonstrating significant market value in the field of cognitive disorder diagnosis and treatment. Based on brain cognitive science and big data artificial intelligence technology, these non-drug treatment technologies have achieved remarkable intervention effects in neurological diseases, mental illnesses, cardiovascular and cerebrovascular diseases, and child development disorders. With the intensification of population aging and the rising incidence of cognitive disorder diseases, the market demand for effective intervention methods is increasing day by day. Digital therapies not only show potential in improving patients' quality of life but also provide medical institutions with precise and efficient diagnostic and treatment tools.
Director, Deputy General Manager and China Market Head of Tuopei Medical Zhao Xiantao
Zhao Xiantao pointed out that the application of optoelectronic technology in medical equipment is showing an innovative development trend. The company has promoted full-domain frequency scanning through the independent research and development of underlying devices.OCTAThe technological breakthroughs in products such as navigation microscopes, panoramic swept-frequency optical biomanometers, and ultra-wide-angle laser confocal fundus cameras in fully digital holography have changed the traditional diagnostic and treatment processes through differentiated advantageous functions.
Chairman and General Manager of Frame Guande Xin Dr. Cao Peiyuan
Dr. Cao Peiyuan pointed out that the company is promoting photon counting based on a large number of underlying foundational technological innovationsXThe industrialization process of ray detection technology. Dr. Cao Peiyuan conducted an in-depth analysis of photon counting.XThe core principle and unique advantages of ray detection technology are demonstrated in this0Breakthroughs in performance such as dark noise, high signal-to-noise ratio, and direct imaging have been achieved, and the working principle is demonstrated through intuitive video demonstrations. In addition, research and development progress of this technology in fields such as medical imaging, scientific research, and industrial non-destructive testing are also discussed. With the gradual rollout of products, photon countingXThe application potential of ray detection technology in multiple fields is becoming increasingly evident.
Founder of Dingke Medical,CEOWeng Yulin
Weng Yulin pointed out that companies involved in balloon businesses in the era of post-purchasing consortia are facing challenges of intensified homogeneous competition and weak innovation. To find new growth points in this red ocean market, differentiation has become a key strategy for companies to gain a foothold in the market. By exploring differentiation in product performance, field selection, and market strategy, companies can stand out in the fierce market competition. For example, innovative balloon products are gradually being launched to meet the special needs of sub-sectors such as dialysis access and peripheral arteries, showing significant market potential. With the increase in uremia patients, the growth in the number of hemodialysis access interventions indicates the huge potential of this market.
Chuangjian MedicalCTODr. Li Haihang
Dr. Li Haihang pointed out that collagen accounts for25%till33%The sources are divided into animal-derived, human-derived materials, and recombinant human-derived materials. China's research and industry on animal collagen started relatively late, with a nearly century-long gap compared to foreign countries. However, in the field of recombinant collagen, China has accelerated its research and industrial development, gradually narrowing the gap with international standards. The performance of recombinant collagen is comparable to that of natural collagen, but2020Annual research shows that recombinant collagen technology has not yet been adopted by the biomedical, pharmaceutical, or food industries.2021In [year], China launched the first implantable Class III medical device, and regulatory policies are also being gradually improved.
General Manager of Rongjing Biology Zhou Zuoyu
Zhou Zuyu pointed out, medical devicesCDMO companySupports the development and large-scale production of complex and diverse medical device products. Medical device products have a long lifecycle and require continuous iteration and cost control. Large medical device platform companies need to monitor market demand,KOLDoctors have their unique strengths, which lead to product ideas and concepts. However, they are not adept at rapidly realizing product design and optimization, large-scale, stable, and low-cost production. High quality can serve international large medical enterprises.CDMO companyThere are fewer platforms, yet demand keeps growing, especially for high-quality products with integrated R&D, design, and mass production capabilities, as well as robust supply chain management.CDMOplatform.
Fine-Management of the Medical Supply ChainSPDRelease Ceremony of the 'Blue Book on the Current Industry Situation and Development Trends'
Consulting Director, Life Sciences Business Unit, Frost & Sullivan Greater China Region Li Qian
Li Qian pointed out that traditional healthcare supply chain management faces challenges due to high costs, low efficiency, and compliance risks.SPDThe concept originated in the United States, matured in Japan, and has rapidly risen in China over the past decade, enhancing the cost-effectiveness of hospitals. As of2023year, ChinaSPDThe penetration rate of the project in public hospitals is6.7%, mainly concentrated in coastal areas, with tertiary general hospitals covering a wide range of areas. Third-party full-chainSPDService providers have highly penetrated the Yangtze River Delta region with their professionalism and collaboration.SPDThe service platform not only addresses the pain points of traditional supply chain businesses but also serves upstream and downstream industries, empowering markets, finance, and other sectors in all aspects. In the future, ChinaSPDThe industry will expand synchronously in depth and breadth.
Roundtable discussion
Roundtable Discussion: How the Medical Device Industry Seizes the Next Trend
The first roundtable discussion was themed 'How the Medical Device Industry Seizes the Next Upcoming Trend.' The discussion was chaired by Hu Hui, co-founder of Dingshen Capital. Guests participating in the discussion included Yin Jie, founder and CEO of Aikema, Dr. Wang Yanguang, founder and CEO of TugMed, Wu Xiaolin, CFO of PAMU Medical, and Tian Jing, Secretary to the Board of Directors of Vise-Akonter.
In this roundtable discussion, the guests delved into the opportunities and challenges faced by the medical device industry, as well as how to identify and utilize the next growth points in the industry. Several guests shared their insights on the development trends of their respective industries, discussing in depth innovative strategies and how to capture the potential of emerging markets and technologies through strategic layout, sharing valuable experiences on how to promote sustainable enterprise development and industry progress.
Roundtable Discussion: Opportunities and Challenges for the Internationalization of Medical Devices
The second roundtable discussion was themed 'Opportunities and Challenges for the Internationalization of Medical Devices'. The discussion was chaired by Liu Xiaolan, Managing Director and Co-Head of the Healthcare Industry Group at CITIC Securities Global Investment Banking. The participants included Pu Fei, Chairman and General Manager of the International Business Unit at Leopar Medical Group; Cai Jin, Chief Financial Officer at Peijia Medical; Li Chen, Business Development Director and Board Secretary at Xianruida Medical; and Zheng Fan, Managing Partner at Yafar Capital.
During this roundtable discussion, the guests jointly explored the opportunities and challenges that the medical device industry may face in the process of internationalization. They shared their insights into global market trends, discussed how to formulate effective internationalization strategies, and how to address regulatory requirements, market access, and cultural differences in different countries and regions. In addition, the guests also had an in-depth exchange on how to use technological innovation and cooperation opportunities to promote the global competitiveness of medical device enterprises.
NIE 2024
More amazing moments✨ 
